Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Insider James Paul Rickey Sells 1,800 Shares
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) insider James Paul Rickey sold 1,800 shares of the stock in a transaction on Monday, December 18th. The stock was sold at an average price of $19.00, for a total value of $34,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
James Paul Rickey also recently made the following trade(s):
On Thursday, December 14th, James Paul Rickey sold 11,600 shares of Alpine Immune Sciences stock. The stock was sold at an average price of $19.00, for a total value of $220,400.00. On Tuesday, December 5th, James Paul Rickey sold 418 shares of Alpine Immune Sciences stock. The stock was sold at an average price of $16.01, for a total value of $6,692.18. On Thursday, November 30th, James Paul Rickey sold 700 shares of Alpine Immune Sciences stock. The shares were sold at an average price of $16.00, for a total value of $11,200.00. On Monday, November 6th, James Paul Rickey sold 18,003 shares of Alpine Immune Sciences stock. The shares were sold at an average price of $16.03, for a total value of $288,588.09. Alpine Immune Sciences Price Performance
ALPN traded up $0.02 during trading on Monday, hitting $18.92. The company had a trading volume of 661,284 shares, compared to its average volume of 308,666. The company has a market cap of $1.10 billion, a PE ratio of -15.77 and a beta of 1.37. The business has a 50-day moving average of $13.23 and a 200-day moving average of $12.39. Alpine Immune Sciences, Inc. has a 1-year low of $5.81 and a 1-year high of $19.27.
Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.11. Alpine Immune Sciences had a negative net margin of 185.10% and a negative return on equity of 33.53%. The firm had revenue of $10.04 million during the quarter, compared to analyst estimates of $8.73 million. Research analysts forecast that Alpine Immune Sciences, Inc. will post -1.1 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on ALPN shares. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Alpine Immune Sciences in a research report on Wednesday, September 13th. Wedbush restated an “outperform” rating and issued a $26.00 price objective on shares of Alpine Immune Sciences in a research report on Wednesday, November 15th. Royal Bank of Canada upped their price objective on Alpine Immune Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd. Morgan Stanley upped their price objective on Alpine Immune Sciences from $17.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, November 3rd. Finally, Oppenheimer upped their price objective on Alpine Immune Sciences from $14.00 to $22.00 and gave the company an “outperform” rating in a research report on Monday, September 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Alpine Immune Sciences has a consensus rating of “Buy” and an average price target of $22.50.
Read Our Latest Stock Report on Alpine Immune Sciences
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in Alpine Immune Sciences by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock valued at $1,062,000 after purchasing an additional 1,216 shares in the last quarter. Royal Bank of Canada boosted its stake in Alpine Immune Sciences by 99.1% during the 2nd quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,315 shares in the last quarter. American International Group Inc. boosted its stake in Alpine Immune Sciences by 26.8% during the 2nd quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 1,543 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Alpine Immune Sciences by 23.4% during the 1st quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,697 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of Alpine Immune Sciences by 20.0% during the 2nd quarter. California State Teachers Retirement System now owns 10,559 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 1,763 shares in the last quarter. 75.17% of the stock is currently owned by institutional investors.
About Alpine Immune Sciences (Get Free Report)
Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alpine Immune Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alpine Immune Sciences wasn’t on the list.
While Alpine Immune Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.